Categories LATEST, Other Industries
Mylan under pressure as shortage of anti-allergy injector persists
Pharmaceutical company Mylan (Nasdaq: MYL), which has been facing criticism for the short supply of its anti-allergy injector EpiPen, suffered a jolt Wednesday following reports that patients and drug retailers are suffering due to the unavailability of the lifesaving medicine. The company’s stock lost sharply soon after trading started.
Adding to the woes of customers, the alternatives to the allergy therapy are either in short supply due to improper distribution or not interchangeable with EpiPen. A generic version being developed by Teva Pharmaceutical (TEVA) will be available only by year-end.
Meanwhile, the hopes of EpiPen supply improving faded after a statement issued by the company recently said the problem will persist in the coming months. The cause for the current crisis dates back to 2017 when inventories were affected by a severe disruption in production. Though the company has a generic alternative, it is not commonly available.
A generic version being developed by Teva Pharmaceutical will be available only by year-end
Amneal Pharmaceuticals (AMRX), the manufacturer of an epinephrine injector that is considered to be an alternative to EpiPen, this week lowered its earnings forecast for fiscal 2019, reflecting the uncertainty over the medicine’s availability. The management also unveiled a reorganization plan with focus on cost-cutting and streamlining of production.
Mylan’s stock dropped more than 5% early Wednesday following reports about the EpiPen shortage, but pared a part of the loss by afternoon and traded around $19. The stock has lost 32% so far this year and 48% in the past twelve months. Meanwhile, shares of Amneal were down 34% in early trading.
Most Popular
Netflix (NFLX) Q1 2024 profit tops expectations; adds 9.3Mln subscribers
Streaming giant Netflix, Inc. (NASDAQ: NFLX) Thursday reported a sharp increase in net profit for the first quarter of 2024. Revenues were up 15% year-over-year. Both numbers exceeded Wall Street's
PepsiCo (PEP) to report Q1 earnings next week. Here’s what to expect
PepsiCo, Inc. (NASDAQ: PEP) is preparing to report first-quarter results on April 23, before the opening bell. Of late, the food and beverage giant has been busy aligning its business
What to expect when Southwest Airlines (LUV) reports Q1 2024 earnings results
Shares of Southwest Airlines Co. (NYSE: LUV) were up 2% on Thursday. The stock has dropped 8% over the past one year. The airline is scheduled to report its first